CFO Jill Ann Howe buys Lineage Cell Therapeutics (LCTX) shares, bringing direct holdings to 45,500.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Jill Ann Howe, CFO of Lineage Cell Therapeutics (LCTX), purchased 20,000 common shares on November 16, 2026, at a weighted average price of $0.855 per share. These transactions, priced between $0.84 and $0.94, increase her direct holdings to 45,500 shares. The purchase was not made under a Rule 10b5-1 plan.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.